TransMedics基本情况
情况介绍
TransMedics, Inc. (TMDX) is a publicly traded company listed on the NASDAQ stock exchange. The company specializes in the development and commercialization of organ care systems that preserve donor organs for transplantation. As of the latest data, TMDX has a market capitalization of approximately $2.5 billion. The company's headquarters is located in Andover, Massachusetts.
股本股东分析
TMDX has a total of 35.5 million shares outstanding. The company's major shareholders include institutional investors such as BlackRock, Vanguard Group, and Fidelity Management & Research Company. Insider ownership is relatively low at around 3%, indicating a strong presence of institutional investors. The stock's average daily trading volume is approximately 300,000 shares, suggesting moderate liquidity.
经营能力分析
TMDX's financial performance has shown significant growth in recent years. In 2022, the company reported revenues of $114 million, a 130% increase from the previous year. The gross margin improved to 65%, reflecting efficient cost management. However, the company remains unprofitable, with a net loss of $35 million in 2022. The operating cash flow was negative at -$25 million, indicating a reliance on external financing to support operations.
竞争能力分析
TMDX operates in a niche market with limited direct competitors. The primary competitors include OrganOx and XVIVO Perfusion. TMDX's Organ Care System (OCS) has a competitive edge due to its ability to maintain organs in a near-physiological state, which can improve transplant outcomes. The company holds several patents that protect its technology, providing a barrier to entry for potential competitors.
发展情景分析
The organ transplantation market is expected to grow at a CAGR of 8% over the next five years, driven by increasing demand for organ transplants and advancements in medical technology. TMDX is well-positioned to capitalize on this growth, with plans to expand its product offerings and enter new markets. The company's pipeline includes next-generation OCS devices that could further enhance its market position.
暂无评论内容